This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early moderate to severe rheumatoid arthritis who completed the WA19926 core study. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01730456?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
